Last reviewed · How we verify
Sorbolene
Sorbolene is a Small molecule drug developed by Trans Tasman Radiation Oncology Group. It is currently in Phase 3 development.
Sorbolene is a light, hydrocarbon-based emulsion used as a topical, external medicine, emollient, and general-purpose substitute for toiletries. It has been studied in clinical trials for conditions such as breast cancer and radiation dermatitis, specifically in comparison to Cavilon Durable Barrier Cream.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Sorbolene |
|---|---|
| Sponsor | Trans Tasman Radiation Oncology Group |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- StrataXRT vs. Standard Clinical Practice in the Prevention and Treatment of Radiation Dermatitis (NA)
- Cavilon Breast Trial: Comparison of Cavilon Durable Barrier Cream to Glycerine ("Sorbolene") Cream (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sorbolene CI brief — competitive landscape report
- Sorbolene updates RSS · CI watch RSS
- Trans Tasman Radiation Oncology Group portfolio CI
Frequently asked questions about Sorbolene
What is Sorbolene?
Who makes Sorbolene?
What development phase is Sorbolene in?
Related
- Manufacturer: Trans Tasman Radiation Oncology Group — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing